LaserSight CEO Discusses Patents and the Industry's Future

Apr 30, 2001, 01:00 ET from LaserSight Incorporated

    WINTER PARK, Fla., April 30 /PRNewswire/ -- This morning, at a press
 conference held during the annual meeting of the American Society of Cataract
 and Refractive Surgery (ASCRS), Michael R Farris, president and chief
 executive officer of LaserSight(R) Incorporated (Nasdaq: LASE) discussed
 LaserSight's view as to how patents and other intellectual properties will
 shape the future of companies participating in the refractive surgery market.
 Mr. Farris commented, "The investment community looks at companies in the
 laser refractive surgery industry as being value based with emphasis on
 state-of-the-art products that capture recurring revenues based on strong and
 enforceable patents."
     Mr. Farris went on to state that, "As a competitor in the refractive
 market, LaserSight's value is based on its proprietary technology, strong
 intellectual property portfolio and its broad range of state-of-the-art
 products that assist refractive surgeons in achieving the best clinical
 outcomes for their patients."
     LaserSight's value is derived from its portfolio of refractive products
 and its owned and licensed patents.  It is LaserSight's intent to realize
 revenue by licensing its patent(s) to other refractive surgery manufacturers.
 The Company's current and future products from which revenues are derived
 include; its LaserScan LSX(R) excimer laser system and associated per
 procedure fees; its AstraMax(TM) integrated diagnostic work station and its
 AstraPro(TM) diagnostic planning software which is currently under development
 and the Company believes will offer an opportunity to charge a premium usage
 fee in both the U.S. and international markets when commercially released; and
 its keratomes and blades.
     The Company's LaserScan LSX excimer laser system is based on precision
 micro-spot scanning technology covered under its U.S. Patent No. 5,520,679
 (the '679 patent).  The LSX(R) incorporates a 0.8 mm high-resolution, super
 gaussian 200 Hz scanning spot that provides an extremely smooth, targeted
 ablation profile for accurate corneal reshaping.  Precision micro-spot
 technology, combined with low fluence and temporal spatial averaging, creates
 a smooth, polished corneal bed that can improve surgical results and minimize
 potential post-surgical problems.
     According to Market Scope's Refractive Market Perspectives, issued in
 August 2000, the U.S. market for excimer lasers is estimated to be 500 systems
 for each of the years 2001 and 2002.  The international market for the same
 period is estimated to be 450 and 475 systems respectively.
     LaserSight recently announced that the U.S. Patent and Trademark Office
 issued a Notice of Allowance for reissue of its '679 patent.  The fundamental
 teachings of the original '679 patent encompass a refractive laser system
 utilizing an excimer laser with a low fluence and high repetition rate that
 ablates corneal tissue using small pulses delivered to the corneal surface in
 an overlapping pattern.  LaserSight was able to broaden several elements of
 the '679 Patent's original claims by removing certain restrictions and by
 adding approximately 68 new claims to better encompass the breadth of
 technology which is covered by the '679 patent.  This reissue allows
 LaserSight to protect the uniqueness of the LaserScan LSX's precision beam
 microspot scanning technology, and provides an opportunity for the Company to
 license its scanning technology to other companies that currently offer, or
 intend to offer, scanning laser systems.  The Company also indicated that it
 has another U.S. scanning patent application undergoing examination that is a
 Continuation in Part of its original application for the '679 patent.  The
 claims in this continuation are comprehensive in nature in that they cover a
 basic laser having a pulsed output laser beam of a fundamental ultraviolet
 wavelength and scanning the pulsed output beam of that laser into a pattern of
 substantially overlapping pulses on tissue such that adjacent ablation spots
 on a single ablation layer of tissue significantly overlap one another.
     Mr. Farris continued, "The reissue of our '679 scanning patent allows
 LaserSight to protect the uniqueness of its LaserScan LSX's precision beam
 microspot scanning technology.  The value of LaserSight's intellectual
 property portfolio has been enhanced by this Notice of Allowance.  During
 prosecution our additional claims were thoroughly reviewed by the Patent and
 Trademark Office and we successfully overcame a third party's spirited
 challenge to our reissue.  The smoothness and precision available with the
 microspot scanning technology incorporated into our LaserScan LSX has become
 an important factor when surgeons are considering a laser purchase.  It is
 recognized that a smooth and uniform ablation must be achieved to deliver the
 high quality custom ablation procedures the market is seeking.  The increasing
 recognition and acceptance of scanning laser technology is apparent from the
 number of our competitors who have introduced some form of a scanning laser
 system into the U.S. market.  The allowance of the '679 patent marks the
 beginning of a new era of next generation technologies and patents for laser
 refractive surgery as refractive surgeons move away from the prior generation
 of broad beam lasers and their related patents."
     LaserSight has already begun notifying the other laser manufacturers as to
 the broad claims added to the '679 Patent as a result of the reissue.  Mr.
 Farris added, "Developing strategic partnerships around our intellectual
 property portfolio will permit LaserSight to maximize its market position.  We
 currently have 22 U.S. patents issued or allowed, and more than 25 additional
 patents pending, all related to the laser vision correction industry.  It is
 the Company's strategy to generate a recurring revenue stream from its
 intellectual properties, and we are currently in discussions regarding other
 strategic opportunities to license certain of our patents.  The '679 scanning
 patent, and its counterpart when reissued, covers the next generation
 technology for laser vision correction and is the technology underlying our
 precision beam microspot scanning LaserScan LSX(R) excimer laser system."
     As previously announced, LaserSight entered into an agreement with Alcon,
 Ft Worth, TX which provided for a time period during which the Company has
 agreed not to claim Alcon infringes the Lin '679 scanning patent and for the
 parties to discuss a possible transaction related to the '679 patent.  On
 March 30, 2001 LaserSight announced that this time period was extended to
 allow discussions to continue.  LaserSight has also received several inquiries
 and has begun discussions with other companies regarding our willingness to
 license our scanning patent and the terms upon which such a license might be
 granted.
     The AstraMax integrated diagnostic workstation is based on technology and
 patents acquired from Premier Laser Systems, Inc.  In March 2000, LaserSight
 purchased all of Premier's intellectual property related to a development
 project that was designed to provide front-to-back analysis and total
 refractive measurement of the eye.  This acquisition has resulted in
 LaserSight currently holding five U.S. patents, six foreign patents, and a
 number of pending patent applications, along with an exclusive license to nine
 additional patents, to the technology that has allowed the Company to complete
 development of the AstraMax and secure its intellectual property rights in
 this new and important diagnostic technology for precision diagnostic
 measurements of the eye needed for customized ablations.
     Among the more important patents related to the AstraMax, are two U.S.
 patents to a multi-camera corneal analysis system that provides faster and
 more accurate measurements than conventional topographers through virtually
 instantaneous image acquisition utilizing a stereo-based multi-camera
 triangulation technology, and a patent covering the method of corneal analysis
 using a checkered polar grid illumination pattern.
     The AstraMax workstation, designed to provide precision diagnostic
 measurements of the eye, is one of the most advanced diagnostic devices
 offered on the market.  Unlike conventional topographers, the AstraMax
 provides complete anterior limbus to limbus topography, posterior corneal
 measurement, scotopic pupil size and anterior chamber depth measurement with a
 single exposure. Currently an ophthalmologist or optometrist would need to
 utilize at least two separate diagnostic instruments to obtain the diagnostic
 information that the AstraMax can acquire.  The diagnostic measurements from
 the AstraMax can be utilized for a broad spectrum of ophthalmic applications.
 An AstraMax integrated workstation can be utilized in both ophthalmic and
 optometric practices for planning ophthalmic procedures that require precise
 and accurate measurements of the eye.  These procedures include contact lens
 fitting, cataract extractions, clear lens extractions, and, when approved,
 planning for customized laser ablations.  All measurements are aligned on a
 common axis and are available for export to LaserSight's AstraPro(TM)
 individualized ablation planning software as part of the Company's
 CustomEyes(TM) approach to custom ablation.
     In 2000, there were approximately 1450 corneal topographers sold
 throughout the world. Sales of topographers are expected to grow to 1725 units
 in 2001 and to 2070 units in 2002. LaserSight believes that an integrated
 diagnostic workstation like the AstraMax, capable of measuring pachymetry and
 pupilometry, in addition to anterior and posterior corneal topography, should
 fill a long expressed need of the market and be able to capture a significant
 share of the corneal topography market.
     As part of LaserSight's Astra family of products for the Company's
 CustomEyes customized ablation products, the AstraMax workstation will provide
 refractive surgeons with the precise diagnostic measurements that are required
 for planning customized ablations with the Company's anticipated AstraPro
 software.  AstraPro is the proposed surgical planning tool that utilizes the
 AstraMax's advanced levels of diagnostic measurements for the planning of
 personalized refractive treatment plans.  Using the same instrument to
 simultaneously obtain all measurements necessary to perform custom ablations
 ensures that all diagnostic data utilized with the AstraPro software during
 the subsequent phase of personalized treatment planning are aligned to the
 patient's optical or visual axis.  LaserSight believes that the AstraPro
 ablation planning software offers an opportunity to capture a stream of
 recurring revenue related to the per procedure fees it intends to charge for
 each use of the software.
     Based on its own market analysis, and supported by information presented
 at the recent Lehman Brothers Healthcare Conference in Orlando, FL, the
 Company believes that refractive surgeons will pay a per procedure fee over
 their standard per procedure fee when offered custom ablation technology
 solutions.  This will also present an opportunity to collect per procedure
 fees from international users.
     The UltraShaper(TM) durable keratome is produced under a license to U.S.
 Patent # RE35, 421 from Luis Ruiz, M.D. and Sergio Lenchig of Bogota,
 Colombia, and is part of LaserSight's MicroShape(R) family of keratome
 products which, in addition to the durable keratome, includes UltraEdge(R)
 keratome blades for both the UltraShaper and ACS keratomes and control
 consoles.  The UltraShaper represents an advancement in design and technology
 that should appeal to all refractive surgeons, but especially those surgeons
 who developed their surgical technique using the previous gold standard
 Automated Corneal Shaper (ACS).  LaserSight's market research shows a strong
 demand for a state-of-the-art keratome that would allow the refractive surgeon
 to use the more conventional ACS surgical technique. According to Market
 Scope's Comprehensive Report on the U.S. Refractive Market (November 2000),
 there were approximately 1400 ACS units placed worldwide, with 600 of those
 units in the U.S. LaserSight has the opportunity to replace a significant
 portion of the ACS installed base with its UltraShaper durable keratome.
     UltraEdge keratome blades are currently sold at a list price of $55 each.
 These blades can be used in the older ACS keratomes as well as in the
 UltraShaper.  In the U.S. conventional LASIK practice is to use a new keratome
 blade for each patient. Since LASIK is generally performed on a bilateral
 basis, the total market for keratome blades is considered to be one half the
 number of procedures performed, or estimated to be performed, in any given
 year.  It is currently estimated that approximately 1.4 million LASIK
 procedures were performed in the U.S. during 2000.  The number of U.S. LASIK
 procedures is anticipated to increase to some where between 1.6 to 1.8 million
 during 2001 and to 2.3 million in 2002.  In addition, the international market
 for LASIK is expected to grow from 1.1 million to 1.7 million procedures
 during the same period.  The total U.S. market for keratome blades is expected
 to grow to $37 million during 2001.
     LaserSight is a leading supplier of quality technology solutions for
 vision correction. Its products include the LaserScan LSX(R) precision beam
 microspot scanning system, its international research and development
 activities related to the Astra family of products used to perform custom
 ablation procedures know as CustomEyes(TM) and its MicroShape(R) family of
 keratome products. In the United States, the Company's LaserScan LSX excimer
 laser system operating at 200 Hz is approved for the treatment of low to
 moderate myopia by photorefractive keratectomy.  The Astra family of products
 includes the AstraMax(TM) diagnostic work station designed to provide precise
 diagnostic measurements of the eye and the AstraPro(TM) software, a surgical
 planning tool that will utilize advanced levels of diagnostic measurements for
 the planning of custom ablation treatments.  The Company has received
 notification from the FDA that it may begin commercial distribution of its
 AstraMax(TM) diagnostic workstation, and has begun international clinical
 evaluation of its AstraPro planning concept.  The MicroShape family of
 keratome products includes the UltraShaper(TM) durable keratome and
 UltraEdge(R) keratome blades.
 
     This press release contains forward-looking statements regarding future
 events and future performance of the Company, including statements with
 respect to the uncertainty associated with intellectual property, potential
 strategic alliances, regulatory approvals and market acceptance of new
 technologies, anticipated sales revenue, regulatory approvals and
 commercialization of products, which involve risks and uncertainties that
 could materially affect actual results.  Investors should refer to documents
 that the Company files from time-to-time with the Securities and Exchange
 Commission for a description of certain factors that could cause the actual
 results to vary from current expectations and the forward looking statements
 contained in this press release.  Such filings include, without limitation,
 the Company's Form 10-K, Form 10-Q and Form 8-K reports.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25223897
 
 

SOURCE LaserSight Incorporated
    WINTER PARK, Fla., April 30 /PRNewswire/ -- This morning, at a press
 conference held during the annual meeting of the American Society of Cataract
 and Refractive Surgery (ASCRS), Michael R Farris, president and chief
 executive officer of LaserSight(R) Incorporated (Nasdaq: LASE) discussed
 LaserSight's view as to how patents and other intellectual properties will
 shape the future of companies participating in the refractive surgery market.
 Mr. Farris commented, "The investment community looks at companies in the
 laser refractive surgery industry as being value based with emphasis on
 state-of-the-art products that capture recurring revenues based on strong and
 enforceable patents."
     Mr. Farris went on to state that, "As a competitor in the refractive
 market, LaserSight's value is based on its proprietary technology, strong
 intellectual property portfolio and its broad range of state-of-the-art
 products that assist refractive surgeons in achieving the best clinical
 outcomes for their patients."
     LaserSight's value is derived from its portfolio of refractive products
 and its owned and licensed patents.  It is LaserSight's intent to realize
 revenue by licensing its patent(s) to other refractive surgery manufacturers.
 The Company's current and future products from which revenues are derived
 include; its LaserScan LSX(R) excimer laser system and associated per
 procedure fees; its AstraMax(TM) integrated diagnostic work station and its
 AstraPro(TM) diagnostic planning software which is currently under development
 and the Company believes will offer an opportunity to charge a premium usage
 fee in both the U.S. and international markets when commercially released; and
 its keratomes and blades.
     The Company's LaserScan LSX excimer laser system is based on precision
 micro-spot scanning technology covered under its U.S. Patent No. 5,520,679
 (the '679 patent).  The LSX(R) incorporates a 0.8 mm high-resolution, super
 gaussian 200 Hz scanning spot that provides an extremely smooth, targeted
 ablation profile for accurate corneal reshaping.  Precision micro-spot
 technology, combined with low fluence and temporal spatial averaging, creates
 a smooth, polished corneal bed that can improve surgical results and minimize
 potential post-surgical problems.
     According to Market Scope's Refractive Market Perspectives, issued in
 August 2000, the U.S. market for excimer lasers is estimated to be 500 systems
 for each of the years 2001 and 2002.  The international market for the same
 period is estimated to be 450 and 475 systems respectively.
     LaserSight recently announced that the U.S. Patent and Trademark Office
 issued a Notice of Allowance for reissue of its '679 patent.  The fundamental
 teachings of the original '679 patent encompass a refractive laser system
 utilizing an excimer laser with a low fluence and high repetition rate that
 ablates corneal tissue using small pulses delivered to the corneal surface in
 an overlapping pattern.  LaserSight was able to broaden several elements of
 the '679 Patent's original claims by removing certain restrictions and by
 adding approximately 68 new claims to better encompass the breadth of
 technology which is covered by the '679 patent.  This reissue allows
 LaserSight to protect the uniqueness of the LaserScan LSX's precision beam
 microspot scanning technology, and provides an opportunity for the Company to
 license its scanning technology to other companies that currently offer, or
 intend to offer, scanning laser systems.  The Company also indicated that it
 has another U.S. scanning patent application undergoing examination that is a
 Continuation in Part of its original application for the '679 patent.  The
 claims in this continuation are comprehensive in nature in that they cover a
 basic laser having a pulsed output laser beam of a fundamental ultraviolet
 wavelength and scanning the pulsed output beam of that laser into a pattern of
 substantially overlapping pulses on tissue such that adjacent ablation spots
 on a single ablation layer of tissue significantly overlap one another.
     Mr. Farris continued, "The reissue of our '679 scanning patent allows
 LaserSight to protect the uniqueness of its LaserScan LSX's precision beam
 microspot scanning technology.  The value of LaserSight's intellectual
 property portfolio has been enhanced by this Notice of Allowance.  During
 prosecution our additional claims were thoroughly reviewed by the Patent and
 Trademark Office and we successfully overcame a third party's spirited
 challenge to our reissue.  The smoothness and precision available with the
 microspot scanning technology incorporated into our LaserScan LSX has become
 an important factor when surgeons are considering a laser purchase.  It is
 recognized that a smooth and uniform ablation must be achieved to deliver the
 high quality custom ablation procedures the market is seeking.  The increasing
 recognition and acceptance of scanning laser technology is apparent from the
 number of our competitors who have introduced some form of a scanning laser
 system into the U.S. market.  The allowance of the '679 patent marks the
 beginning of a new era of next generation technologies and patents for laser
 refractive surgery as refractive surgeons move away from the prior generation
 of broad beam lasers and their related patents."
     LaserSight has already begun notifying the other laser manufacturers as to
 the broad claims added to the '679 Patent as a result of the reissue.  Mr.
 Farris added, "Developing strategic partnerships around our intellectual
 property portfolio will permit LaserSight to maximize its market position.  We
 currently have 22 U.S. patents issued or allowed, and more than 25 additional
 patents pending, all related to the laser vision correction industry.  It is
 the Company's strategy to generate a recurring revenue stream from its
 intellectual properties, and we are currently in discussions regarding other
 strategic opportunities to license certain of our patents.  The '679 scanning
 patent, and its counterpart when reissued, covers the next generation
 technology for laser vision correction and is the technology underlying our
 precision beam microspot scanning LaserScan LSX(R) excimer laser system."
     As previously announced, LaserSight entered into an agreement with Alcon,
 Ft Worth, TX which provided for a time period during which the Company has
 agreed not to claim Alcon infringes the Lin '679 scanning patent and for the
 parties to discuss a possible transaction related to the '679 patent.  On
 March 30, 2001 LaserSight announced that this time period was extended to
 allow discussions to continue.  LaserSight has also received several inquiries
 and has begun discussions with other companies regarding our willingness to
 license our scanning patent and the terms upon which such a license might be
 granted.
     The AstraMax integrated diagnostic workstation is based on technology and
 patents acquired from Premier Laser Systems, Inc.  In March 2000, LaserSight
 purchased all of Premier's intellectual property related to a development
 project that was designed to provide front-to-back analysis and total
 refractive measurement of the eye.  This acquisition has resulted in
 LaserSight currently holding five U.S. patents, six foreign patents, and a
 number of pending patent applications, along with an exclusive license to nine
 additional patents, to the technology that has allowed the Company to complete
 development of the AstraMax and secure its intellectual property rights in
 this new and important diagnostic technology for precision diagnostic
 measurements of the eye needed for customized ablations.
     Among the more important patents related to the AstraMax, are two U.S.
 patents to a multi-camera corneal analysis system that provides faster and
 more accurate measurements than conventional topographers through virtually
 instantaneous image acquisition utilizing a stereo-based multi-camera
 triangulation technology, and a patent covering the method of corneal analysis
 using a checkered polar grid illumination pattern.
     The AstraMax workstation, designed to provide precision diagnostic
 measurements of the eye, is one of the most advanced diagnostic devices
 offered on the market.  Unlike conventional topographers, the AstraMax
 provides complete anterior limbus to limbus topography, posterior corneal
 measurement, scotopic pupil size and anterior chamber depth measurement with a
 single exposure. Currently an ophthalmologist or optometrist would need to
 utilize at least two separate diagnostic instruments to obtain the diagnostic
 information that the AstraMax can acquire.  The diagnostic measurements from
 the AstraMax can be utilized for a broad spectrum of ophthalmic applications.
 An AstraMax integrated workstation can be utilized in both ophthalmic and
 optometric practices for planning ophthalmic procedures that require precise
 and accurate measurements of the eye.  These procedures include contact lens
 fitting, cataract extractions, clear lens extractions, and, when approved,
 planning for customized laser ablations.  All measurements are aligned on a
 common axis and are available for export to LaserSight's AstraPro(TM)
 individualized ablation planning software as part of the Company's
 CustomEyes(TM) approach to custom ablation.
     In 2000, there were approximately 1450 corneal topographers sold
 throughout the world. Sales of topographers are expected to grow to 1725 units
 in 2001 and to 2070 units in 2002. LaserSight believes that an integrated
 diagnostic workstation like the AstraMax, capable of measuring pachymetry and
 pupilometry, in addition to anterior and posterior corneal topography, should
 fill a long expressed need of the market and be able to capture a significant
 share of the corneal topography market.
     As part of LaserSight's Astra family of products for the Company's
 CustomEyes customized ablation products, the AstraMax workstation will provide
 refractive surgeons with the precise diagnostic measurements that are required
 for planning customized ablations with the Company's anticipated AstraPro
 software.  AstraPro is the proposed surgical planning tool that utilizes the
 AstraMax's advanced levels of diagnostic measurements for the planning of
 personalized refractive treatment plans.  Using the same instrument to
 simultaneously obtain all measurements necessary to perform custom ablations
 ensures that all diagnostic data utilized with the AstraPro software during
 the subsequent phase of personalized treatment planning are aligned to the
 patient's optical or visual axis.  LaserSight believes that the AstraPro
 ablation planning software offers an opportunity to capture a stream of
 recurring revenue related to the per procedure fees it intends to charge for
 each use of the software.
     Based on its own market analysis, and supported by information presented
 at the recent Lehman Brothers Healthcare Conference in Orlando, FL, the
 Company believes that refractive surgeons will pay a per procedure fee over
 their standard per procedure fee when offered custom ablation technology
 solutions.  This will also present an opportunity to collect per procedure
 fees from international users.
     The UltraShaper(TM) durable keratome is produced under a license to U.S.
 Patent # RE35, 421 from Luis Ruiz, M.D. and Sergio Lenchig of Bogota,
 Colombia, and is part of LaserSight's MicroShape(R) family of keratome
 products which, in addition to the durable keratome, includes UltraEdge(R)
 keratome blades for both the UltraShaper and ACS keratomes and control
 consoles.  The UltraShaper represents an advancement in design and technology
 that should appeal to all refractive surgeons, but especially those surgeons
 who developed their surgical technique using the previous gold standard
 Automated Corneal Shaper (ACS).  LaserSight's market research shows a strong
 demand for a state-of-the-art keratome that would allow the refractive surgeon
 to use the more conventional ACS surgical technique. According to Market
 Scope's Comprehensive Report on the U.S. Refractive Market (November 2000),
 there were approximately 1400 ACS units placed worldwide, with 600 of those
 units in the U.S. LaserSight has the opportunity to replace a significant
 portion of the ACS installed base with its UltraShaper durable keratome.
     UltraEdge keratome blades are currently sold at a list price of $55 each.
 These blades can be used in the older ACS keratomes as well as in the
 UltraShaper.  In the U.S. conventional LASIK practice is to use a new keratome
 blade for each patient. Since LASIK is generally performed on a bilateral
 basis, the total market for keratome blades is considered to be one half the
 number of procedures performed, or estimated to be performed, in any given
 year.  It is currently estimated that approximately 1.4 million LASIK
 procedures were performed in the U.S. during 2000.  The number of U.S. LASIK
 procedures is anticipated to increase to some where between 1.6 to 1.8 million
 during 2001 and to 2.3 million in 2002.  In addition, the international market
 for LASIK is expected to grow from 1.1 million to 1.7 million procedures
 during the same period.  The total U.S. market for keratome blades is expected
 to grow to $37 million during 2001.
     LaserSight is a leading supplier of quality technology solutions for
 vision correction. Its products include the LaserScan LSX(R) precision beam
 microspot scanning system, its international research and development
 activities related to the Astra family of products used to perform custom
 ablation procedures know as CustomEyes(TM) and its MicroShape(R) family of
 keratome products. In the United States, the Company's LaserScan LSX excimer
 laser system operating at 200 Hz is approved for the treatment of low to
 moderate myopia by photorefractive keratectomy.  The Astra family of products
 includes the AstraMax(TM) diagnostic work station designed to provide precise
 diagnostic measurements of the eye and the AstraPro(TM) software, a surgical
 planning tool that will utilize advanced levels of diagnostic measurements for
 the planning of custom ablation treatments.  The Company has received
 notification from the FDA that it may begin commercial distribution of its
 AstraMax(TM) diagnostic workstation, and has begun international clinical
 evaluation of its AstraPro planning concept.  The MicroShape family of
 keratome products includes the UltraShaper(TM) durable keratome and
 UltraEdge(R) keratome blades.
 
     This press release contains forward-looking statements regarding future
 events and future performance of the Company, including statements with
 respect to the uncertainty associated with intellectual property, potential
 strategic alliances, regulatory approvals and market acceptance of new
 technologies, anticipated sales revenue, regulatory approvals and
 commercialization of products, which involve risks and uncertainties that
 could materially affect actual results.  Investors should refer to documents
 that the Company files from time-to-time with the Securities and Exchange
 Commission for a description of certain factors that could cause the actual
 results to vary from current expectations and the forward looking statements
 contained in this press release.  Such filings include, without limitation,
 the Company's Form 10-K, Form 10-Q and Form 8-K reports.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25223897
 
 SOURCE  LaserSight Incorporated